Go Pro
→ Gold Explorer Sits Between Barrick’s Nevada Giants (From Wall Street Logic) (Ad)tc pixel Free COIL Stock Alerts

Roquefort Therapeutics (COIL) Competitors

Roquefort Therapeutics logo
GBX 8.60 +0.10 (+1.18%)
As of 07:25 AM Eastern
Compare

COIL vs. CIR, TILS, VSN, SCLP, and MPH

Should you buy Roquefort Therapeutics stock or one of its competitors? Roquefort Therapeutics's main competitors and comparable companies include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), and Mereo BioPharma Group plc (MPH.L) (MPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Circassia Group?

Circassia Group (LON:CIR) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Circassia Group has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Circassia Group's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

1.9% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Roquefort Therapeutics Neutral

Circassia Group has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Circassia Group beats Roquefort Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Roquefort Therapeutics (LON:COIL) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

1.9% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Tiziana Life Sciences N/A N/A N/A

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Tiziana Life Sciences Neutral

Tiziana Life Sciences has lower revenue, but higher earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Summary

Roquefort Therapeutics and Tiziana Life Sciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Roquefort Therapeutics (LON:COIL) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
VerseonN/AN/AN/A-£14.30N/A

1.9% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Verseon N/A N/A N/A

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Verseon Neutral

Summary

Verseon beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Scancell?

Scancell (LON:SCLP) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Roquefort Therapeutics has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M21.37-£6.75M-£0.55N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Scancell has a net margin of -116.98% compared to Roquefort Therapeutics' net margin of -57,057.07%. Scancell's return on equity of 90.29% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

In the previous week, Scancell had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Roquefort Therapeutics. Scancell's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Scancell Neutral
Roquefort Therapeutics Neutral

Scancell has a beta of 0.687, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

1.5% of Scancell shares are held by institutional investors. Comparatively, 1.9% of Roquefort Therapeutics shares are held by institutional investors. 15.5% of Scancell shares are held by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Scancell beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

1.9% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Roquefort Therapeutics Neutral

Summary

Mereo BioPharma Group plc (MPH.L) beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COIL vs. The Competition

Export
MetricRoquefort TherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£36.70M£3.94B£7.16B£2.90B
Dividend YieldN/A3.61%2.54%6.17%
P/E Ratio-0.3911.87272.62367.23
Price / SalesN/A1,336.63621.9883,303.86
Price / Cash1.4944.0628.7827.89
Price / Book2.2517.0711.137.02
Net Income-£1.52M-£22.72M£3.47B£5.89B
7 Day Performance-7.82%-3.17%-1.66%0.47%
1 Month Performance-12.24%10.47%7.09%3.60%
1 Year Performance-42.67%52.98%23.37%22.41%

Roquefort Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COIL
Roquefort Therapeutics
N/AGBX 8.60
+1.2%		N/A-37.5%£36.70MN/AN/A9
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
SCLP
Scancell
N/AGBX 9.65
+0.3%		N/A-11.4%£100.15M£4.71MN/A51

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 9/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel